NEWSROOM | Galderma

Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo

Q-Med discontinues the Breast Indication for Macrolane

Galderma announces Completion of Phase 3 Trials of Investigational Drug targeting Facial Erythema of Rosacea

Ipsen and Galderma increase their collaboration for Dysport® in new territories

Galderma receives FDA Approval for new convenient Pump Dispenser of Differin Gel, 0.3% for treatment of Acne Vulgaris

Galderma Announces Availability of New Metrogel 1% Pump Dispenser for the Treatment of Papulopustular Rosacea

Galderma announces positive US pivotal interim 6-month results for EMERVEL Classic Lidocaine compared to JUVEDERM Ultra

Galderma announces positive Phase 2B Results for Investigational Compound targeting Redness of Rosacea

AstraZeneca and Galderma enter into R&D collaboration to develop new treatments for dermatological diseases

Galderma Launches EMERVEL® Range of Hyaluronic Acid Dermal Fillers

Galderma announces Results of largest-ever Rosacea Trial

Cetaphil® Brand Launches Cetaphil® Restoraderm® -- a new Line of Products to Help